Margaret A Horn

COO Margaret A Horn sells 93,575 shares for $14,972,110.02 via scheduled 10b5-1 plan; holds 411,800 derivative shares post-sale.

Margaret A Horn, COO of Revolution Medicines, executed 3 separate sales totaling 93,575 shares for $14,972,110.02 at an average price of $160.00 per share on 2025-06-16. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2023-05-31, meaning the sales were scheduled rather than discretionary. After the sales, Horn retains 154,647 non-derivative shares and holds 411,800 shares through 5 in-the-money stock option vehicles, demonstrating continued meaningful economic interest in the company. Revolution Medicines is unprofitable, reporting net income of $-453,816,000.00 in its latest period with zero revenue, while the stock has appreciated significantly in the prior 90 days (+58.9%) and currently trades at $157.77, near the blended sale price of $160.00.

COO Margaret A Horn sells 10,000 shares ($1.5M) via pre-arranged 10b5-1 plan at RVMD

Margaret A Horn, Chief Operating Officer, executed 7 separate sales totaling 10,000 shares for $1,480,139.48 on 2026-06-11 via a pre-arranged 10b5-1 trading plan adopted on 2026-03-12. The blended average sale price was $148.01, while the current price stands at $160.06 (52-week high $166.50), meaning the transaction occurred below the recent peak. Because this sale is part of a scheduled, non-discretionary 10b5-1 plan, it reflects a pre-planned capital allocation rather than a discretionary response to current market conditions. The insider retains 158,222 non-derivative shares post-transaction and holds 91,194 shares through derivative securities (stock options), so the position was not exited. Over the past 30 days the stock has appreciated 9.9%, and over 90 days 61.5%, though the insider's prior same-ticker sales at RVMD (5 prior trades) have generally been followed by modest negative returns in the 90-day window. The company remains unprofitable with a negative net income of $-453,816,000 in the latest full year, warranting attention to the fundamental backdrop against which this scheduled sale occurred.

COO Horn sells 75,000 RVMD shares for $7.5M at blended $100.56; stock now $118.64, 52.3% higher in 30 days

Margaret A Horn, Chief Operating Officer, executed 3 separate sales totaling 75,000 shares for $7,542,022.50, reducing her holdings by 34.7% from 216,053 to 141,053 shares. The sales occurred at prices ranging from $100.02 to $102.90 on 2026-01-07, with a blended average of $100.56, yet RVMD's current price stands at $118.64—17.8% above the transaction prices—signaling the insider sold before a substantial rally. The timing pattern at this ticker shows mixed results: 3 of 5 prior sales were eventually well-timed at the 90-day mark, though her cross-ticker timing has been stronger (75.00% well-timed rate across all holdings). RVMD remains unprofitable with a $-305.2M net loss in the most recent period and zero revenue recognition, raising questions about whether the elevated price reflects fundamental improvements or momentum-driven valuation that preceded the insider's exit decision.

COO Margaret A Horn sold 50,000 RVMD shares at $50.34 on 2024-10-11, reducing holdings by -27.4%.

Margaret A Horn, Chief Operating Officer of Revolution Medicines, sold 50,000 shares (50.0K shares) at $50.34 on 2024-10-11, representing a -27.4% reduction in her post-transaction holdings to 132,320 shares (132.3K shares). This is a material open-market sale by an executive at a company with concerning fundamentals: Revenue was $0.00 in the latest quarter, the company posted a net loss of $-133,233,000.00 (annual), and annual revenue growth was -67.3% year-over-year. The stock is currently trading at $48.99, just -3.0% from its 52-week high of $50.48, yet Horn's prior two sales at this ticker (both on 2024-03-12 and 2024-03-11) were followed by positive 30- and 90-day returns of +9.8%/+17.0% and +7.3%/+18.6% respectively, while three earlier 2023-10-16 sales preceded declines. The $2.5M sale by a senior executive at an unprofitable, negative-revenue biotech raises questions about operational cash burn and insider conviction amid deteriorating top-line metrics.